NCT06446661 Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
| NCT ID | NCT06446661 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Acute Lymphoblastic Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2026-05-19 |
| Primary Completion | 2027-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2026-05-19 with a primary completion date of 2027-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.
Eligibility Criteria
Inclusion Criteria: * Age of 15 years or older at time of enrollment * Diagnosed with ALL or T-cell lymphoblastic lymphoma * Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention. Exclusion Criteria: * Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages * Patient does not wish to participate * Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.
Contact & Investigator
Austin Wesevich
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06446661 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying Acute Lymphoblastic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06446661 currently recruiting?
Yes, NCT06446661 is actively recruiting participants. Contact the research team at cancerclinicaltrials@bsd.uchicago.edu for enrollment information.
Where is the NCT06446661 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06446661 clinical trial?
NCT06446661 is sponsored by University of Chicago. The principal investigator is Austin Wesevich at University of Chicago. The trial plans to enroll 48 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.